A nexus of miR-1271, PAX4 and ALK/RYK influences the cytoskeletal architectures in Alzheimer's Disease and Type 2 Diabetes. Issue 17 (17th September 2021)

• Record Type: Journal Article
• Authors: Majumder, Piyali; Chanda, Kaushik; Das, Debajyoti; Singh, Brijesh Kumar; Chakrabarti, Partha; Jana, Nihar Ranjan; Mukhopadhyay, Debashis
• Is Part Of: Biochemical journal. Volume 478:Issue 17(2021)
• Page Start: 3297
• Page End: 3317
• Publication Date: 2021-09-17
• Subjects: Alzheimer's disease -- cytoskeleton -- receptor tyrosine kinases -- transcription factors -- type 2 diabetes; Biochemistry -- Periodicals; 572
• DOI: 10.1042/BCJ20210175
• Languages: English
• ISSNs: 0264-6021

Abstract

Abstract : Alzheimer's Disease (AD) and Type 2 Diabetes (T2D) share a common hallmark of insulin resistance. Reportedly, two non-canonical Receptor Tyrosine Kinases (RTKs), ALK and RYK, both targets of the same micro RNA miR-1271, exhibit significant and consistent functional down-regulation in post-mortem AD and T2D tissues. Incidentally, both have Grb2 as a common downstream adapter and NOX4 as a common ROS producing factor. Here we show that Grb2 and NOX4 play critical roles in reducing the severity of both the diseases. The study demonstrates that the abundance of Grb2 in degenerative conditions, in conjunction with NOX4, reverse cytoskeletal degradation by counterbalancing the network of small GTPases. PAX4, a transcription factor for both Grb2 and NOX4, emerges as the key link between the common pathways of AD and T2D. Down-regulation of both ALK and RYK through miR-1271, elevates the PAX4 level by reducing its suppressor ARX via Wnt/β-Catenin signaling. For the first time, this study brings together RTKs beyond Insulin Receptor (IR) family, transcription factor PAX4 and both AD and T2D pathologies on a common regulatory platform.